Page 23 - Pharma Sector

Aurobindo arm TheraNym inks pact with MSD for biologics manufacturing

This agreement follows previous disclosures by Aurobindo Pharma about expanding its biologics manufacturing facilities and exploring contract manufacturing operations (CMO) for biologicals

Why did investors dump Marksans Pharma shares post Q4 results? Know here

Marksans Pharma's net profit fell 4.5 per cent on a year-on-year (Y-o-Y) basis to Rs 78.3 crore in the March quarter of FY24, from Rs 82 crore in the March quarter of FY23

Deepening presence in Tier-III may be Dr Lal PathLabs' growth pill

Manchanda highlights that the 'white-spaces' for them are going deeper in strong markets

Drugmakers to see FY25 revenue boost in key US market: India Ratings

The world's largest drug market is facing decade-high drug shortages, the research firm said in a note citing data from with Utah Drug Information Service

Aurobindo Pharma Q4 results: PAT rises 79.5% to Rs 908 cr, revenue up 14.8%

The increase in PAT is attributed to expansion into the new markets, product launches and stable pricing

Emcure Pharma, HDT settle legal fight over Covid vaccine technology

The companies said they have signed a long-term agreement to continue collaborating on the development of mRNA-based vaccines and a license that allows Emcure to use HDT's mRNA technology

Stock trading guide for today: How to approach pharma, FMCG counters?

Technical indicators such as the RSI, MACD, and Stochastic are showing signs of potential correction and underperformance for the Nifty Pharma index

Weak Q4 due to lower growth may be rare bitter pill for Sun Pharma

Sun Pharma is in the process of acquiring US-based Taro Pharmaceuticals and taking it private

Sun Pharma Q4 result: Profit up 33% over strong US, specialty sales

Firm guides for high single-digit top line, higher R&D spend in FY25; board approves appointment of Dilip Shanghvi as chairman

JB Pharma aims to grow its revenue by 12-14% in the next two years

JB Pharma plans to maintain its presence in cardiology, focusing on hypertension, heart failure, and lipid-lowering treatments

Indian pharma firms supplied 47% of all generic prescriptions in US in 2022

Indian pharmaceutical companies also accounted for a lower but important share of biosimilar production, manufacturing 15 per cent of biosimilar volume used by US patients in 2022

Pharma major Glenmark gets USFDA nod for generic ophthalmic solution

Glenmark Pharmaceuticals Ltd on Friday said it has received final approval from the US health regulator for its generic brimonidine tartrate and timolol maleate ophthalmic solution indicated in the treatment increased pressure in the eye caused by glaucoma or other conditions. The final approval by the US Food & Drug Administration (USFDA) is for brimonidine tartrate and timolol maleate ophthalmic solution of strength 0.2 per cent/0.5 per cent, Glenmark said in a statement. The company's brimonidine tartrate and timolol maleate ophthalmic solution, 0.2 per cent/0.5 per cent has been determined by the USFDA to be bioequivalent and therapeutically equivalent to Combigan ophthalmic solution, 0.2 per cent/0.5 per cent of AbbVie, Inc, it added. The solution will be distributed in the US by Glenmark Pharmaceuticals Inc, USA, it added. Combigan ophthalmic solution, 0.2 per cent/0.5 per cent achieved annual sales of approximately USD 290 million, the company said citing IQVIATM sales data

Diabetes to infections: NPPA slashes retail prices of 41 essential drugs

Prices of essential drugs such as dapagliflozin metformin hydrochloride, used for lowering blood glucose levels by decreasing glucose production in the liver, have been fixed at Rs 16 per tablet

Mankind Pharma open to acquisitions; board okays Rs 7,500 cr fundraise

The drug maker was reportedly interested in buying private equity (PE) firm Advent International's stake in Mumbai-based biopharma firm Bharat Serums and Vaccines (BSV)

Cipla promoters sell 2.53% stake worth Rs 2,637 cr to fund philanthropy

ICICI Prudential MF, Aditya Birla Sun Life MF among top buyers

Granules India Q4 results: Revenue declines 1.6% on weak paracetamol sales

The company's consolidated revenue fell year-on-year to 1,176 crore rupees (nearly $141 million) for the three months to March 31

Cipla zooms 5% on 2.53% stake sale by Hamied family, Okasa Pharma

Promoters Shirin Hamied, Rumana Hamied, Samina Hamied and Okasa Pharma Private Limited have sold 2.53 per cent shares of Cipla for an undisclosed amount

Promoter group to sell 2.53% stake worth $316 million in Cipla: Report

The promoter group will sell its stake in Cipla at a per-share price range of 1,289.5 rupees to 1,357.35 rupees, the report said

Mankind Pharma in fray to acquire Advent's stake in Bharat Serums: Report

Mankind Pharma's stock surged 3.11 per cent on BSE on Tuesday

Zydus Wellness Q4: Net profit up 3.44% to Rs 150 cr, revenue at 782 cr

Zydus Wellness Ltd on Tuesday reported a 3.44 per cent rise in consolidated net profit at Rs 150.3 crore in the fourth quarter ended March 31, 2024. The company had posted a consolidated net profit of Rs 145.3 crore in the same quarter of the previous fiscal, Zydus Wellness said in a regulatory filing. Consolidated total revenue from operations in the quarter under review stood at Rs 782.6 crore, as against Rs 713 crore in the corresponding period a year ago, it said. Total expenses were higher at Rs 632.2 crore in the fourth quarter of financial year 2023-24, as compared to Rs 580.2 crore in the year-ago period. For the fiscal ended March 31, 2024 consolidated net profit was at Rs 266.9 crore, as against Rs 310.4 crore in the previous fiscal, the company said. In FY24, consolidated total revenue from operations stood at Rs 2,327.8 crore, as compared to Rs 2,254.8 crore in FY23. The board of directors at their meeting held on May 14, 2024 recommended a final dividend Rs 5 per equ